Abstract 1999P
Background
Antibody‒drug conjugates (ADCs) have dramatically improved clinical outcomes in urothelial cancers as a novel, effective and low-toxicity therapeutic approach recently. However, previous studies ignored the expression heterogeneity of ADCs-relative genes in metastatic tissues of pN+ patients, which are the crucial populations to improve overall outcomes. Here, we aimed to explore HER2, HER3, Nectin4 and Trop2 expression in advanced urothelial cancers between primary tumors and metastatic lymph nodes (mLN) in pairs.
Methods
306 pN+ urothelial cancer patients including 65 renal pelvis, 38 ureter, 179 bladder and 24 urethral cancer from SYSUCC were included. The IHC scores of 2/3+ were defined as HER2 high expression. HER3, Nectin4 and Trop2 were evaluated by H-scores (range 0-300, rank 0 to 3+) which multiplied by the extent and intensity of the staining, and H-scores >15 were considered positive.
Results
HER2 positive expression (1-3+) was detected in 74.8% advanced urothelial cancers and 49.4% patients were HER2 high expression (2/3+). HER2 high expression rate of renal pelvis, ureter, bladder and urethral primary tumors were 33.8%, 42.2%, 56.5% and 50%, while 30.1%, 41.7%, 51.9% and 50% in mLN respectively. The concordance rate of HER2 expression between primary and mLNs was 71.9%. Meanwhile, 27.7%, 42.1%, 52%, and 66.7% primary tumors of renal pelvis, ureter, bladder and urethral cancer patients had HER3 positive expression (71.9% in consistency with mLN); 72.3%, 89.5%, 77.7%, 87.5% positive expression rate for Nectin4 (50.7% in consistency); 89.2%, 94.7%, 83.2%, 95.8% positive expression rate for Trop2 (65.3% in consistency). Furthermore, survival analysis showed that HER2, HER3 and Trop2 overexpression were associated with poor OS (p<0.05), and only HER2 overepxression in mLNs was independent unfavourable prognostic factor.
Conclusions
We first investigated the expression heterogeneity of ADC-related targets in primary urothelial tumors and mLNs in a large cohort, especially in pN+ patients. Therapy targeting HER2-ADCs might show better homogeneity in advanced disease, but it is more recommended to detect IHC staining both in primary and metastatic tissues to guide subsequent treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Natural Science Foundation of Guangdong Province, China, No. 2022A1515012318.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
246P - Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Presenter: Anna C. Weiss
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
248P - Impact of unilateral mastectomy with or without immediate breast reconstruction on vertebral alignment
Presenter: Jong-Ho Cheun
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13